|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.50 USD | -1.22% |
|
0.00% | -7.71% |
| 02-24 | UBS Adjusts Price Target on Pediatrix Medical to $22 From $23, Maintains Neutral Rating | MT |
| 02-20 | Deutsche Bank Cuts Price Target on Pediatrix Medical Group to $19 From $21, Keeps Hold Rating | MT |
| Capitalization | 1.6B 1.37B 1.24B 1.19B 2.17B 147B 2.24B 14.63B 5.86B 70.47B 6.01B 5.88B 252B | P/E ratio 2026 * |
9.82x | P/E ratio 2027 * | 9.59x |
|---|---|---|---|---|---|
| Enterprise value | 1.72B 1.48B 1.34B 1.28B 2.34B 158B 2.41B 15.74B 6.3B 75.82B 6.46B 6.33B 271B | EV / Sales 2026 * |
0.89x | EV / Sales 2027 * | 0.8x |
| Free-Float |
98.33% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Pediatrix Medical Group, Inc.
| 1 day | -1.09% | ||
| Current month | -0.55% | ||
| 1 month | -6.40% | ||
| 3 months | -7.67% | ||
| 6 months | +19.13% | ||
| Current year | -7.71% |
| 1 week | 18.86 |  | 20.29 |
| 1 month | 17.23 | | 22.06 |
| Current year | 17.23 | | 22.84 |
| 1 year | 11.84 | | 24.99 |
| 3 years | 6.62 | | 24.99 |
| 5 years | 6.62 | | 35.68 |
| 10 years | 6.62 | | 76.96 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Ordan
CEO | Chief Executive Officer | 67 | 2025-01-12 |
Kasandra Rossi
DFI | Director of Finance/CFO | 53 | 2024-09-30 |
| Compliance Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Ordan
CHM | Chairman | 67 | 2022-12-31 |
Guy Sansone
CHM | Chairman | 61 | 2020-07-11 |
Thomas McEachin
BRD | Director/Board Member | 73 | 2020-07-11 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.22% | 0.00% | +37.56% | +36.23% | 1.6B | |
| -0.76% | -0.77% | +59.94% | +118.02% | 120B | |
| -0.08% | -5.18% | +17.00% | -1.01% | 97.1B | |
| -1.79% | -1.52% | +23.92% | +99.12% | 31.68B | |
| -0.64% | +3.90% | -6.11% | -0.60% | 23.23B | |
| -0.14% | -5.05% | +10.06% | +20.72% | 22.14B | |
| -0.66% | -3.58% | +16.05% | +49.58% | 22.07B | |
| -0.80% | -2.25% | +88.20% | +351.54% | 20.65B | |
| -0.85% | -2.59% | +42.91% | +61.95% | 16.6B | |
| -0.71% | +0.31% | -11.75% | +5.85% | 12.62B | |
| Average | -0.80% | -0.88% | +27.78% | +74.14% | 36.79B | |
| Weighted average by Cap. | -0.66% | -1.76% | +33.96% | +73.89% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.93B 1.66B 1.5B 1.43B 2.62B 177B 2.7B 17.62B 7.06B 84.87B 7.23B 7.08B 304B | 1.98B 1.7B 1.54B 1.47B 2.68B 182B 2.77B 18.08B 7.24B 87.1B 7.42B 7.27B 312B |
| Net income | 164M 141M 127M 122M 222M 15.05B 229M 1.5B 600M 7.22B 615M 602M 25.84B | 172M 148M 133M 128M 233M 15.79B 241M 1.57B 629M 7.57B 645M 632M 27.1B |
| Net Debt | 122M 104M 94.41M 90.39M 165M 11.17B 170M 1.11B 445M 5.36B 456M 447M 19.18B | -19.67M -16.89M -15.27M -14.62M -26.7M -1.81B -27.55M -180M -72.02M -866M -73.83M -72.27M -3.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-03-10 | 19.74 $ | -1.79% | 654,381 |
| 26-03-09 | 20.10 $ | +1.77% | 1,098,896 |
| 26-03-06 | 19.75 $ | +2.38% | 1,173,635 |
| 26-03-05 | 19.29 $ | -2.97% | 821,210 |
| 26-03-04 | 19.88 $ | +0.71% | 753,859 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MD Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition